Loading...
•
Dec 31, 2019
Cue Biopharma Q4 2019 Earnings Report
Cue Biopharma reported fourth quarter and full year 2019 financial results.
Key Takeaways
Cue Biopharma reported collaboration revenue of $1.0 million for the fourth quarter of 2019, and cash and cash equivalents of $59.4 million as of December 31, 2019. The company focused on clinical development of CUE-101 and made progress on its Immuno-STAT™ Platform.
Extended cash runway with $33.3 million from at-the-market equity offerings in Q4 2019.
Focused on clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and expansion trial in HNSCC.
Immuno-STAT™ Platform for autoimmune disease featured in Merck presentation at the Antigen-Specific Immune Tolerance Drug Development Summit.
Published paper on preclinical and translational data supporting the therapeutic potential of CUE-101 in HPV16-related malignancies in peer-reviewed journal Clinical Cancer Research
Cue Biopharma
Cue Biopharma
Cue Biopharma Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com